CClinicalTrials.gg
Status unknownNCT00894296Updated Jan 5, 2012

Magnetoencephalographic (MEG) Correlates of Negative Symptoms in Patients Suffering From Schizophrenia and Their Influence by Add-on Treatments

An observational study in Schizophrenia, sponsored by Shalvata Mental Health Center. Status unknown at 1 site in Israel. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2012-01-05.

Sponsored by Shalvata Mental Health Center · Observational

The sponsor has not verified this record recently (last verified Jan 2012), so the status shown — last known as Recruiting — may be out of date.
Study type
Observational
Model
Case-control
Time perspective
Prospective
Enrollment
50
Ages
18 Years to 65 Years
Sex
All
01

Study summary

The objective of the suggested study is to identify changes in MEG correlates caused by the add-on treatment with the changes in negative symptoms of schizophrenia by comparing the change in the MEG correlates of the subjects before and during usage of new add on treatments for negative symptoms.

The investigators hypothesize that the gravity of negative symptoms will correlate with a trend towards more aberrant electroencephalographic correlates mainly in continuous parameters, with an emphasis on alpha and delta bands

Read the detailed description

There is a paucity of information regarding electrophysiological correlates of negative symptoms in patients suffering from schizophrenia. The proposed study is set out to compare the MEG correlates of negative symptoms in patients suffering from schizophrenia to those of healthy controls in terms of both relevant ERP components and quantified (continuous) MEG.

The presented study will include two parts: Part A will explore the electrophisological correlates of negative symptoms in patients suffering from schizophrenia using MEG. The study will do so by comparing the electrophisological correlates of schizophrenia patients suffering from negative symptoms and stable on psychiatric treatment to those of healthy controls. In the second part of the study data from part A of patients that have started new add-on treatments for negative symptoms will be compared to parallel data acquired after stabilization on the new treatment.

02

Conditions studied

  • Schizophrenia

Browse trials for

Keywords

  • MEG
  • schizophrenia
  • negative symptoms
03

In context

Schizophrenia

3,471 studies on the registry are indexed under Schizophrenia; 472 are open to participants now.

This study's planned enrollment of 50 is below the median of 178 across 491 observational studies indexed under Schizophrenia.

Browse Schizophrenia studies →

Lead sponsor

Shalvata Mental Health Center is the lead sponsor of 73 studies on the registry; 6 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

schizophrenia patients and healthy subjects between the ages 18-65

Eligibility criteria

Inclusion Criteria:

  • Study Group (Schizophrenia Patients) Inclusion Criteria
  • Patients between the ages of 18-65 (male and female), Diagnosed in the past as suffering from schizophrenia. The diagnosis will be reaffirmed according to ICD criteria.
  • Right hand dominant.
  • Scores in PANSS negative questionnaire above 21 and positive symptom less than 24.
  • Gave informed consent for participation in the study.
  • Stable on the same antipsychotic medication for at least a month prior to entering the study Control Group (healthy Subjects)

Inclusion criteria:

  • Healthy man and woman
  • Ages 18-65
  • Right handed

Exclusion Criteria:

  • Study Group (Schizophrenia Patients) (To prevent MEG artifacts by non relevant electric interference or brain conditions)
  • History of epilepsy, seizure, or hot spasm, sever head injuries.
  • History of metal in the head (outside the mouth space).
  • History of surgery including metal implant or history of metal particles in the eye, pacemaker, or any other medical pump.
  • History of migraines.
  • History of drug or alcohol abuse during the last year. Inability to achieve satisfying level of communication with the subject Control Group (healthy Subjects)
  • History of psychiatric diagnosis
  • Drug or alcohol addiction in the year prior to the study
  • History of epilepsy, seizure, or hot spasm.
  • History of head injuries.
  • History of metal in the head (outside the mouth space).
  • History of surgery including metal implant or history of metal particles in the eye, pacemaker, or any other medical pump.
  • History of migraines.
  • Use of psychotropic medication
05

Study design

Observational model
Case-control
Time perspective
Prospective
Enrollment
50 participants (estimated)

Groups and cohorts

  • 1

    schizophrenia patients

  • 2

    healthy control

06

What researchers measure

Primary outcomes

  1. Primary outcome measures will include continuous and ERP (Event Related Potential) MEG (Magnetoencephalograph) data

    Time frame: four months

07

Study locations

1 of 1 sites recruiting
  • Bar-Ilan University
    Givat Shmuel, Israel
    • Liron Rabani, MA · Contact · 7478644
    • Liron Rabany, MA · Principal investigator
    Recruiting
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jan 5, 2012, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00894296
Lead sponsor
Shalvata Mental Health Center
Collaborators
Bar-Ilan University, Israel
Responsible party
Sponsor
First posted
May 6, 2009
Start date
Mar 2009
Primary completion
Jan 2013 (estimated)
Completion
Jan 2013 (estimated)
Last update
Jan 5, 2012

Study contacts

Liron Rabani, MA
Contact
972-97478644 ext. 09

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Jan 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion